Massachusetts General Hospital logoHarvard Medical School logoMGH Psychosis Consultation ServiceDepartment of Psychiatry
Back to what we provide

Treatment-resistant schizophrenia

Why Recognizing Treatment Resistance Promptly Matters

Persistent symptoms do not always mean treatment-resistant schizophrenia. A careful assessment can identify other reasons for limited improvement and determine whether treatment resistance is truly present.[1] If confirmed, clozapine is recommended, with the person’s individual benefits and risks considered.[2]

Continue to key points

Reasons recognizing treatment-resistant schizophrenia matters

  • Persistent symptoms can disrupt everyday life

    Ongoing psychosis can interfere with relationships, school, work, and independence. The impact is not only the symptoms themselves, but also the parts of life they interrupt.[4]

  • Recognizing resistance helps avoid ineffective medication switches

    Once treatment resistance is established, repeated switches between similar antipsychotic medications can prolong symptoms and side effects without enough relief. Recognizing it helps identify when a different approach is needed.[2]

  • Clozapine is the only FDA-approved antipsychotic for treatment-resistant schizophrenia

    A careful evaluation can help confirm whether treatment resistance is truly present, identify addressable reasons for poor response, and assess whether clozapine is appropriate and how its risks can be managed safely.[1,2,6]

  • Longer delays are linked to a lower chance of responding to clozapine

    Among people with treatment-resistant schizophrenia, longer delays before starting clozapine are associated with a lower chance of symptom improvement once clozapine treatment begins. This supports avoiding unnecessary delays when clozapine is appropriate.[3]

Evidence snapshot

How common is it?

About 1 in 3

people with schizophrenia experience treatment resistance.[5]

Estimates vary across studies.

When does it begin?

Follow-up studies found that most people who developed treatment resistance had it from their first episode of psychosis. Others developed it later.[7,8]

The bottom line

Treatment resistance does not mean treatment cannot help. It means a different approach may be needed. Timely recognition can help avoid unnecessary delays in considering clozapine, while keeping symptom relief and everyday life at the center of care.[2,4]

References

  1. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216-29.
  2. Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020;177(9):868-72.
  3. Shah P, Iwata Y, Plitman E, Brown EE, Caravaggio F, Kim J, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. Psychiatry Res. 2018;268:114-22.
  4. National Institute of Mental Health. Schizophrenia. Patient and family information.
  5. Diniz E, Fonseca L, Rocha D, Trevizol A, Cerqueira R, Ortiz B, et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. Braz J Psychiatry. 2023;45(5):448-58.
  6. U.S. Food and Drug Administration. FDA briefing document: Risk Evaluation and Mitigation Strategy (REMS) for clozapine products. Joint advisory committee meeting, November 19, 2024. Background: treatment-resistant schizophrenia.
  7. Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46(15):3231-40.
  8. Demjaha A, Lappin JM, Stahl D, Patel MX, MacCabe JH, Howes OD, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981-89.